However, the ability of R2-Pep to reduce CHOP expression to normal physiological levels offers the opportunity to prevent CHOP-mediated cell death in pathological conditions primary unrelated to GABAB receptors such as diabetes (Oyadomari et al., 2002), asthma (Wang et al., 2017) or Alzheimer’s (Prasanthi et al., 2011). This evidence concerns the gene DDIT3 and diabetes mellitus.